Amicogen, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021
November 15, 2021 at 07:54 am
Share
Amicogen, Inc. reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported sales was KRW 946.13 million compared to KRW 560.31 million a year ago. Net loss was KRW 20,758.86 million compared to net income of KRW 7,608.22 million a year ago. Basic loss per share from continuing operations was KRW 1,071 compared to basic earnings per share from continuing operations of KRW 396 a year ago. Diluted loss per share from continuing operations was KRW 1,044 compared to diluted earnings per share from continuing operations of KRW 396 a year ago. Basic loss per share was KRW 1,071 compared to basic earnings per share of KRW 396 a year ago. Diluted loss per share was KRW 1,044.
For the nine months, sales was KRW 3,246.87 million compared to KRW 5,192.12 million a year ago. Net income was KRW 24,220.9 million compared to KRW 22,623.21 million a year ago. Basic earnings per share from continuing operations was KRW 1,257 compared to KRW 1,178 a year ago. Diluted earnings per share from continuing operations was KRW 1,255 compared to KRW 1,178 a year ago. Basic earnings per share was KRW 1,257 compared to KRW 1,178 a year ago. Diluted earnings per share was KRW 1,255.
Amicogen, Inc. is a Korea-based company engaged in the development, production and distribution of enzymes, bio new materials and healthcare food. The Companyâs products consist of special enzymes, N-acetylglucosamine (NAG), pinitol, D-Chiro-inositol (DCI), collagen peptides (CP) and protein A chromatography resins. The Company distributes its products within domestic market and to overseas markets, including China, Japan, the United Sates, Germany and Thailand.
AMICOGEN, INC. 
